Advertisement

Related Videos

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Jun
28
Today In Oncology
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo